LOOP DIURETIC TORASEMID IN THE TREATMENT OF ARTERIAL HYPERTENSION


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article focuses on torasemide as a drug of choice for arterial hypertension management. Diuretics are a first line group in pharmacotherapy of this pathology, however the group is highly geterogenic. Preference for torasemide is based upon its pharmacokinetic specifics and blockage of aldosterone effects, that it leads to pleiotropic positive effects. Evidence data is considered for torasemide prescription in arterial hypertension, as the aspects of its effect in cardiovascular comorbidities.

全文:

受限制的访问

作者简介

Ivan GORDEEV

N.I. Pirogov Russian National Research Medical University

Email: cardio-15@yandex.ru
MD, Professor, Head of the Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St

Yevgeniy TARATUKHIN

N.I. Pirogov Russian National Research Medical University

PhD, Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St

Oksana BAIKOVA

N.I. Pirogov Russian National Research Medical University

MD, Professor, Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St

参考

  1. Глобальные цели ВОЗ по неинфекционным заболеваниям к 2025 году (Global Voluntarily Goals for non-communicable diseases 2025 (URL: http://www.who.int/nmh/ncd-tools/definition-targets/en/)
  2. Libby P., Bonow R.O., Mann D.L. et al. Braunwald's Heart Disease (8th ed.). Elsevier, 2008. 2274 p.
  3. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б., Белявская Д.В., Выдрина О.И., Пастернак Е.Ю., Белоусов Д.Ю. и группа исследователей. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV: приверженность врачей. Российский кардиологический журнал. 2015;1(1 17):59-66
  4. Фомин В.В. Антиальдостероновое действие торасемида: случайность или необходимость? РМЖ. 2012;14:693
  5. Теплова Н.В., Таратухин Е.О. Злокачественная артериальная гипертензия. Palmarium Acad Publish, 2014. 300 с
  6. Kumar N., Calhoun D.A., Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr. Blood Press. Control. 2013;6:139-51.
  7. Tamargo J., Segura J., Ruilope L.M. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Exp. Opin. in Pharmacotherapy. 2014;15(5):605-21.
  8. Roush G.C., Kaur R., Ernst M.E. Diuretics: a review and update. J. of Cardiovasc. Pharm. and Therapeutics. 2014;19(1 ):5-13.
  9. Adam O., Zimmer C., Hanke N., Hartmann R.W., Klemmer B., Böhm M., Laufs U. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice. J. Mol. Cell Cardiol. 2015;85:140-50.
  10. Mentz R.J., Hasselblad V., DeVore A.D., Metra M., Voors A.A., Armstrong P.W., Ezekowitz J.A., Tang W.H., Schulte P.J., Anstrom K.J., Hernandez A.F., Velasquez E.J., O'Connor C.M. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF Trial). Am J. Cardiol. 2016;117(3):404-1 1.
  11. Haider D.G., Lindner G., Wolzt M., Leichte A.B., Fiedler G.-M., Sauter T.C., Fuhrmann V., Exadaktylos A.K. Use of diuretics is not associated with mortality in patients admitted to the emergency department: results from a cross-sectional study. J. of Negative Results in Biomedicine. 2016; 1; 44; doi: 10.1186/s12952-016-0044-1.
  12. Mann S.J., Ernst M.E. Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention. Current Hypertens. Reports. 2015; 17:30-39.
  13. Malha L., Mann S.J. Loop diuretics in the treatment of hypertension. Curr. Hypertens. Rep. 2016;18(4):27.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##